DYEE Capital

Dyee Capital is an investment firm established in June 2016 and based in Xiamen, China. Specializing in early and growth stage venture capital, the firm actively seeks investment opportunities in private equity as well. Dyee Capital focuses on sectors including information services, consumption, and medical and healthcare, aiming to support innovative companies in these fields.

Zhang Li

Executive Director

Dezhen Zhu

Founder, Chairman and Managing Partner

53 past transactions

Air white whale

Series A in 2025
Beluga Airlines is a large-scale unmanned cargo aircraft R&D and manufacturing company.

Weikaier Pharmaceutical Technology

Series C in 2024
Weikaier Pharmaceutical provides R&D of innovative drugs, transfer of generic drug technology, the production and sales of pharmaceuticals.

Huayuan Regenerative Medicine

Seed Round in 2023
Huayuan Regenerative Medicine is the manufacture of implantable bioartificial organs. Huayuan Regenerative Medicine is committed to the research and development, production, and sales of clinical grade stem cells, biological tissue engineering products, and biomanufacturing. Their clinical products include urinary kidney precursor cells, dialysis equipment, and a biosynthetic artificial pancreas.

Jinfang Pharmaceutical

Series C in 2023
Jinfang Pharmaceutical is focused on R&D and drug development from small molecule drug pipelines to diversified cutting-edge therapies.

Genepoint Biological Technology

Series D in 2023
Genepoint Biological Technology, based in Shanghai, China, specializes in manufacturing and distributing advanced devices for cryogenic biomaterial storage and handling. Their product portfolio includes automated cryo-bio storage systems, hybrid cryo-storage solutions, LIN vapor freezers, and specialized hoists for freezers, catering to life sciences researchers. The company is committed to advancing IoT, automation, and intelligence technologies in the field of cryogenic biomaterial management.

ininin.com

Venture Round in 2022
Ininin is a technology service company in the packaging industry. They are creating digital business value in the packaging industry through the integration of cloud computing, big data, and machine intelligence integration of cloud computing, big data, and machine intelligence. They offer production and sales collaboration across the supply chain of paper packaging. They provide digital supply chain service solutions for the packaging industry, connecting various packaging factories, software and hardware manufacturers, and service providers in the industry through the packaging industry cloud.

Beijing Weilan New Energy Technology

Series D in 2022
Beijing Weilan New Energy Technology is an enterprise company focusing on the development and production of next-generation all-solid-state batteries. One of the battery companies with patents and technologies for all-solid-state battery cores. With the core concept of “Huijuwei Blue, Leading Solid State”, the company has a leading domestic and international leading technology and development team. The company was established in 2016 and is based in Beijing, China.

BridGene Biosciences

Series B in 2022
BridGene Biosciences is a biotechnology company focused on discovering and developing innovative small molecules aimed at traditionally untreatable targets. By utilizing advanced chemoproteomic technology, the company facilitates proteome-wide screening in live cells, which allows for the identification of highly selective small molecules. BridGene employs a combination of covalent chemistry, chemical proteomics, and quantitative mass spectrometry to create therapeutics and covalent small-molecule inhibitors. This approach positions BridGene to enable the healthcare industry to uncover new drug targets and develop effective treatments for challenging conditions.

Degron Therapeutics

Series A in 2022
Degron Therapeutics is a drug discovery company focused on developing a new class of therapeutics centered around targeted protein degradation. The company specializes in molecular glue degrader drugs, which are small molecules designed to selectively target and degrade specific proteins associated with various diseases. Degron Therapeutics aims to lead the field of small molecule molecular glue degrader medicines by leveraging its expertise to identify and validate challenging disease targets that traditional small molecule inhibitors cannot effectively address. The company is committed to addressing unmet medical needs across a broad range of therapeutic areas by developing innovative protein degradation drugs, utilizing its advanced molecular glue platform technology to enhance treatment efficacy.

MicroClear Medical

Series C in 2022
MicroClear Medical specializes in the development and manufacturing of medical instruments aimed at enhancing ophthalmology and optometry imaging services. The company offers a range of high-quality optical equipment, including a confocal retinal ophthalmoscope, a handheld fundus camera, a handheld slit lamp, and a vision screener. Utilizing artificial intelligence technology, MicroClear's products are designed to facilitate improved diagnostic accuracy for healthcare professionals. The company serves hospitals and basic medical institutes worldwide, providing accessible and advanced imaging solutions to support eye care.

Cloudbreak Therapeutics

Series C in 2022
Cloudbreak Therapeutics LLC, established in 2015 and based in Irvine, California, is a biotechnology company specializing in the development of ocular drugs. It focuses on repurposing approved systemic drugs for eye delivery, aiming to treat glaucoma and pterygium diseases efficiently. The company operates a capital-efficient model, utilizing contract research organizations (CROs) to maximize resources for drug development. Its business strategy involves advancing drug candidates through proof-of-concept Phase II clinical trials and subsequently out-licensing global rights for Phase III trials, registration, and commercialization.

TenaFe

Venture Round in 2022
TenaFe, Inc. is a technology company based in Campbell, California, that specializes in the development of solid-state drive (SSD) controllers. Founded in 2018, TenaFe focuses on creating innovative solutions for data storage challenges across various applications, including client devices, data centers, and emerging edge technologies. The company's patented technology aims to enhance the reliability, performance, and energy efficiency of SSDs, catering to a diverse range of devices from personal computers to connected gadgets. By leveraging its advanced controller technology, TenaFe seeks to provide clients with improved storage solutions that meet the evolving demands of modern data management.

GenFleet Therapeutics

Series C in 2021
GenFleet Therapeutics, established in 2017 and headquartered in Shanghai, China, is a biotechnology company focused on cancer research and development. It specializes in creating therapeutic molecules, including signal transduction regulators, tumor microenvironment modulators, and transcription factors, to target various cancer systems. The company aims to develop innovative molecular-level pharmaceuticals and antibody drugs that can effectively stimulate the body's immune response against tumors. GenFleet serves both domestic and international clients.

Innogen Pharmaceutical

Series A in 2021
Innogen Pharmaceutical Technology is an international biopharmaceutical company specializing in the development and manufacturing of innovative drugs. The company utilizes advanced genetic engineering and recombinant protein biopharmaceutical processes to create new therapies. Its primary focus is on addressing the treatment needs of patients suffering from diabetic metabolic diseases and significant central nervous system disorders. Through its research and development efforts, Innogen aims to deliver effective solutions that enhance patient care and improve health outcomes.

Manteia

Venture Round in 2021
Manteia Technology is a radiology systems company established in 2017 and headquartered in Xiamen, China, with a wholly-owned subsidiary in the United States. The company specializes in developing advanced radiotherapy solutions for cancer treatment, leveraging deep learning, data technology, and traditional algorithms. Manteia's research and development teams, which comprise approximately 50 professionals, including a significant proportion of doctors and master's degree holders, are dedicated to creating innovative software for automatic target volume delineation, dose calculation, and intelligent adaptive radiotherapy systems. The company's expertise is evidenced by over 170 published scientific papers in radiotherapy, along with 26 software copyrights, 2 international patents, and 6 domestic patents. Manteia has received recognition as a "Double Hundred Talents" enterprise by the Xiamen Municipal Government and has garnered strategic investments from notable organizations in the radiotherapy sector.

Zhimeng Biopharma

Series B in 2021
Zhimeng Biopharma, established in 2017 and headquartered in Shanghai, China, specializes in developing innovative medicines for chronic hepatitis B (CHB) and related liver diseases. Its portfolio includes HBV capsid inhibitor (CB-001), HBsAg inhibitor, TLR8 agonist, OX-40 agonist, and KCNQ2/3 K+ channel opener for epilepsy. Additionally, Zhimeng is actively exploring novel small molecule drugs to address neurological conditions like epilepsy, pains, and strokes.

Sinotau

Series D in 2021
SinoTau is a comprehensive solution provider in the pharmaceutical sector, focusing on both generic and innovative drugs. The company specializes in the early development of antibody biopharmaceuticals and produces advanced generic medications. It aims to address various therapeutic areas, including cardiovascular diseases, neurodegeneration, and tumors. SinoTau's expertise encompasses medicinal chemical synthesis, generic drug analysis, pharmaceutical preparations, and drug registration, supported by leading research in targeted drug development. The company leverages advanced diagnostic methods and monoclonal antibody technologies to enhance its offerings, positioning itself as a key player in the biotechnology industry.

Leads Biolabs

Series C in 2021
Leads Biolabs is a biotechnology company based in China that focuses on developing innovative antibody-based therapeutics for oncology and immunological diseases. Founded in 2014, the company is dedicated to addressing global unmet medical needs by creating biopharmaceutical products that enhance treatment outcomes for patients. Leads Biolabs has established a strong research and development pipeline, featuring over ten projects centered on monoclonal and bispecific antibodies aimed at cancer immunotherapy. Through its commitment to advancing tumor immunotherapy, the company strives to improve the medical treatment and overall conditions of patients facing cancer.

Zenova Pharmaceutical

Series A in 2021
Zenova Pharmaceutical specializes in the fields of research and development of new drugs, research, and development of high-end complex pharmaceutical preparations and specialty drugs.

Ionova Life Science

Venture Round in 2021
Ionova Life Science Co., Ltd. is a biotechnology company founded in 2016 and based in Shenzhen, China, with additional offices in Hong Kong, Macao, and the Greater Bay Area. The company specializes in the discovery and development of novel medicines for cancer treatment, focusing on oncology, including immune-oncology and targeted delivery approaches. Ionova is dedicated to creating innovative tumor-targeted drugs and immunomodulatory therapies for cancer and related diseases, employing its proprietary discovery platform to advance its research and product development initiatives.

FABU.ai

Series B in 2021
Fabu Technology Limited, founded in 2017 and based in Hangzhou, China, specializes in providing software and hardware solutions for autonomous driving and related technologies. The company develops advanced systems that include autonomous driving solutions for cargo trucks, ranging from levels 2 to 4, as well as advanced driver assistance systems designed to enhance safety and efficiency in vehicles with significant blind spots. Fabu's technology leverages machine learning, computer vision, and robotics to support unmanned horizontal transportation systems in automated terminals. By integrating artificial intelligence, Fabu aims to streamline operations in the logistics and shipping industries, improving scheduling efficiency, reducing labor costs, and decreasing turnaround times in port operations.

Elpiscience Biopharmaceuticals

Series C in 2021
Elpiscience Biopharmaceuticals Co., Ltd. is a clinical-stage biopharmaceutical company based in Pudong, China, with an additional office in Suzhou. It specializes in developing next-generation immunotherapies aimed at treating cancer. The company boasts a robust pipeline of innovative molecules that target a wide array of challenges in immuno-oncology. Founded by experienced leaders and scientists in the biopharmaceutical field, Elpiscience is committed to advancing at least one innovative molecule into clinical trials each year, with the goal of improving treatment options for cancer patients globally.

Phanes Therapeutics

Series B in 2021
Phanes Therapeutics, Inc. is a biotechnology company based in San Diego, California, established in 2016. It specializes in drug discovery and early development in the fields of immuno-oncology and eye diseases. The company is developing a range of therapeutic molecules, including monoclonal antibodies targeting solid tumors and conditions such as age-related macular degeneration, diabetic macular edema, and diabetic retinopathy. In addition, Phanes Therapeutics is working on bispecific antibodies aimed at treating small cell lung cancer. With a strong foundation in scientific knowledge and innovation, the company is committed to advancing effective treatment options and improving patient outcomes on a global scale.

Innogen Pharmaceutical

Venture Round in 2021
Innogen Pharmaceutical Technology is an international biopharmaceutical company specializing in the development and manufacturing of innovative drugs. The company utilizes advanced genetic engineering and recombinant protein biopharmaceutical processes to create new therapies. Its primary focus is on addressing the treatment needs of patients suffering from diabetic metabolic diseases and significant central nervous system disorders. Through its research and development efforts, Innogen aims to deliver effective solutions that enhance patient care and improve health outcomes.

SceneRay

Series D in 2021
SceneRay Co. Ltd, based in Singapore Industrial Park in Suzhou, China, is a medical device company specializing in the design, development, and distribution of neuromodulation devices. The company focuses on creating advanced medical products, including a dual-channel implantable pulse generator kit for deep brain stimulation. This technology is designed to provide effective treatments for patients suffering from brain damage through electric stimulation. SceneRay's core team comprises experts with extensive experience in neuromodulation device development, manufacturing, and marketing, both in China and internationally. The company holds numerous patents and is committed to exploring innovative solutions in the field of neuromodulation, aiming to deliver high-quality and effective treatments to improve patient outcomes.

FutureGen

Series B in 2021
FutureGen is a biopharmaceutical company focused on the development of innovative biologics, specifically in the fields of immunology and cancer. The company is dedicated to creating and commercializing novel antibody drugs aimed at improving treatment outcomes for cancer and tumor-related diseases. FutureGen utilizes its proprietary Structure-based Targeted Evolution Platform, which is an advanced screening technology designed for efficient protein drug screening. This platform allows for the rapid identification and production of optimal antibodies. With a strong background in medication development, clinical research, and quality management, FutureGen aims to enhance treatment options for patients through its groundbreaking research and development efforts.

Ark Biosciences

Series C in 2021
Ark Biosciences Inc. is a biopharmaceutical company based in Shanghai, China, specializing in the discovery and development of therapeutics aimed at addressing unmet medical needs, particularly in the areas of respiratory viral infections and viral hepatitis. Founded in 2013, the company focuses on developing innovative treatments, including AK0701 for chronic obstructive pulmonary disease, AK0529 for respiratory syncytial virus, AK0612 for influenza, and AK0705 and AK0706 for hepatitis B. Ark Biosciences is committed to advancing antiviral drug research and development to serve both global and Chinese markets.

Maxi Novel

Series C in 2021
Maxi Novel specializes in the fields of oral combination of tumor immunity, targeted drugs, and chemotherapy drugs.

Innovision

Seed Round in 2021
Innovision is a company that specializes in developing auxiliary diagnosis and treatment systems tailored for endoscopy centers in hospitals. By leveraging artificial intelligence deep learning technology, Innovision processes digestive endoscopy image data to assist in medical imaging-assisted diagnosis of the digestive system. This innovative approach helps hospitals enhance work efficiency and alleviate the workload on endoscopy doctors, ultimately reducing the need for redundant labor.

InventisBio

Series D in 2020
InventisBio Inc. is a biotechnology company focused on discovering and developing innovative therapeutics for cancer and metabolic diseases. Founded in 2013 and based in Pudong, China, the company has developed a range of small molecule drug candidates targeting lung cancer, breast cancer, and gout. Among its notable products is D-0316, a third-generation EGFR-T790M tyrosine kinase inhibitor. InventisBio is also engaged in creating targeted immuno-oncology therapies that can be used in combination with existing treatments, such as PD-1 antibodies, to address various cancer indications. Co-founded by Dr. Yaolin Wang and a team of scientists with extensive experience in drug discovery at major pharmaceutical companies, InventisBio aims to provide effective therapies for significant health challenges.

KYEE

Series D in 2020
KYEE is a manufacturer of products and services for the medical cloud business that covers many fields, such as medical cloud, smart ward, and big data in health care. The company's process of deepening medical information technology. KYEE helps medical institutions improve service quality and efficiency, ensuring medical safety effectively.

LP Pharmaceuticals

Series C in 2020
LP Pharmaceuticals (Xiamen) Co., Ltd., located in Xiamen Biomedical Industry Base which formulates and manufactures pharmaceuticals with enhanced delivery properties. The company was founded in 2012 by a group of scientists and business professionals with extensive experience in the US and Chinese pharmaceutical industry. Proprietary delivery platforms include mucosal and oral controlled release. Therapeutic areas currently concern central nervous system, digestive system, cardiovascular, cancer and AIDS.

Innovision

Seed Round in 2019
Innovision is a company that specializes in developing auxiliary diagnosis and treatment systems tailored for endoscopy centers in hospitals. By leveraging artificial intelligence deep learning technology, Innovision processes digestive endoscopy image data to assist in medical imaging-assisted diagnosis of the digestive system. This innovative approach helps hospitals enhance work efficiency and alleviate the workload on endoscopy doctors, ultimately reducing the need for redundant labor.

Elpiscience Biopharmaceuticals

Series B in 2019
Elpiscience Biopharmaceuticals Co., Ltd. is a clinical-stage biopharmaceutical company based in Pudong, China, with an additional office in Suzhou. It specializes in developing next-generation immunotherapies aimed at treating cancer. The company boasts a robust pipeline of innovative molecules that target a wide array of challenges in immuno-oncology. Founded by experienced leaders and scientists in the biopharmaceutical field, Elpiscience is committed to advancing at least one innovative molecule into clinical trials each year, with the goal of improving treatment options for cancer patients globally.

Ionova Life Science

Series A in 2019
Ionova Life Science Co., Ltd. is a biotechnology company founded in 2016 and based in Shenzhen, China, with additional offices in Hong Kong, Macao, and the Greater Bay Area. The company specializes in the discovery and development of novel medicines for cancer treatment, focusing on oncology, including immune-oncology and targeted delivery approaches. Ionova is dedicated to creating innovative tumor-targeted drugs and immunomodulatory therapies for cancer and related diseases, employing its proprietary discovery platform to advance its research and product development initiatives.

A1Food

Series B in 2019
A1Food is a food and snacks brand which mainly sells nuts and pastry. Its products offered includes nut set, nut seaweed, oxcake, and blasting liquid crisp. A1Food food sells its product online. The company was founded in 2018 and is headquartered in Xiamen, Fujian.

Allist Pharmaceuticals

Series A in 2019
Allist Pharmaceuticals is a pharmaceutical company based in Shanghai that focuses on discovering, developing, and commercializing innovative medicines, particularly in the field of cancer treatment. The company is driven by the unmet clinical needs within the global pharmaceutical market and is committed to advancing long life through scientific and technological innovation. Allist Pharmaceuticals aims to create safe, effective, and inclusive drugs, holding independent intellectual property rights for its products.

HeBaoDan

Seed Round in 2019
HeBaoDan is an innovative S2B2C e-commerce platform that focuses on enhancing the online retail experience. The company operates a new retail platform aimed at facilitating Internet retail by developing a unique business model that combines social interaction with shopping. HeBaoDan promotes an engaging community shopping experience, allowing consumers to connect while making purchases. By leveraging technology and a modern approach to retail, the company seeks to transform how consumers engage with brands and products online.

Zongmu

Series C in 2018
Zongmu Technology Co. Ltd, established in 2013, is a Shanghai-based company specializing in automotive industry solutions and integration services. It operates research and development centers in Beijing and Shenzhen. Zongmu is renowned for its SurroundView ADAS (Advanced Driving Assistance System), which has been successfully implemented in major OEM automotive markets. The company has formed strategic partnerships with several OEM car manufacturers and tier-1 suppliers, solidifying its position as the leading SurroundView ADAS solution provider in the Chinese domestic market.

Weijiechengpei

Series B in 2018
Weijiechengpei is a third-party logistics service provider based in urban areas, specializing in the distribution of goods for sectors such as catering, retail, and fresh e-commerce. Operating under the service brand Shanghai Kexin Logistics Co., Ltd., the company employs a model that combines consultation with logistics services. It focuses on B2B logistics management, particularly for restaurant and retail chains, and emphasizes logistics integration and the construction of B2B logistics networks. Weijiechengpei offers a range of services, including warehousing, distribution, packaging, and supply chain consulting, aimed at enhancing operational efficiency for its clients in the fast-moving consumer goods market and beyond.

FineEx

Series C in 2018
FineEx is a prominent logistics service provider specializing in e-commerce warehouse logistics. The company has established itself as a leading third-party logistics enterprise by leveraging a comprehensive national warehousing network. FineEx offers an integrated logistics platform that combines advanced warehouse management and distribution capabilities, catering to the needs of both brand owners and distributors. By utilizing self-developed logistics systems and intelligent hardware, FineEx enhances the efficiency of warehousing operations and delivery processes for e-commerce and traditional retail businesses. This approach enables clients to reduce warehousing costs, improve turnover, and elevate the overall delivery experience.

BornsRobot

Series A in 2018
Borns Robot Co., Ltd. is a manufacturer of surgical robots based in Chongqing, China, with an additional office in Chengdu. The company specializes in developing intelligent medical devices designed for minimally invasive surgery, focusing on porous laparoscopy technologies. Borns Robot aims to enhance surgical procedures by providing digital diagnosis and treatment solutions that cater to the needs of both doctors and patients. Through its innovative approach, the company addresses specific clinical requirements in the field of non-invasive surgery.

KTVme

Series B in 2018
KTVme is a digital entertainment platform that aims to enhance the traditional television experience through music. It offers a unique service that allows users to order party songs and control set-top boxes, effectively transforming the way karaoke is experienced at home or in social settings. By providing a tailored selection of music, KTVme enables users to enjoy their preferred songs, making it a versatile option for entertainment. The platform is designed to create an engaging atmosphere for various gatherings, catering to the entertainment needs of its users.

SpaceGen

Venture Round in 2018
Xiamen SpaceGen Co., Ltd. is a company focused on the development and manufacturing of diagnostic and monitoring products aimed at cancer and genetic diseases. Established in 2015 and headquartered in Xiamen, China, SpaceGen offers a range of clinical-grade detection kits designed for various cancers, including lung, breast, and colon cancer. The company's product lineup includes diagnostic reagents and mutation detection kits, which cater to the needs of medical professionals and patients seeking personalized precision medical testing solutions. By emphasizing innovation in individualized testing services, SpaceGen strives to enhance the quality of medical diagnostics in the field of oncology and genetic disorders.

Huiyi Huiying

Venture Round in 2018
Huiyi Huiying is an international cloud computing, large data & AI tech that has created a digital medical imaging and tumor radiotherapy platform. It has also built a video intelligent screening system, leak detection system and the image Depth applied to the tumor, cardiovascular, acute abdomen and other single disease of artificial intelligence assisted diagnosis and treatment system.

A1Food

Series A in 2017
A1Food is a food and snacks brand which mainly sells nuts and pastry. Its products offered includes nut set, nut seaweed, oxcake, and blasting liquid crisp. A1Food food sells its product online. The company was founded in 2018 and is headquartered in Xiamen, Fujian.

Xiao Qu Hao Hushi

Series A in 2017
Xiao Qu Hao Hushi provides online medical consultancy services through an application.

Zongmu

Series B in 2017
Zongmu Technology Co. Ltd, established in 2013, is a Shanghai-based company specializing in automotive industry solutions and integration services. It operates research and development centers in Beijing and Shenzhen. Zongmu is renowned for its SurroundView ADAS (Advanced Driving Assistance System), which has been successfully implemented in major OEM automotive markets. The company has formed strategic partnerships with several OEM car manufacturers and tier-1 suppliers, solidifying its position as the leading SurroundView ADAS solution provider in the Chinese domestic market.

JDT

Venture Round in 2017
JDT focuses in providing technical products and solutions across the value chain for enterprises, governments and other customers.

Yidian Zixun

Venture Round in 2017
Yidian Zixun is a mobile news aggregator founded in 2013 and headquartered in Beijing, China. The platform utilizes advanced search and recommendation technologies to deliver personalized content to its users. By analyzing user data, Yidian creates individual profiles that help define personal interests, allowing for the targeted distribution of news and media. The company employs professionals to generate content, rewarding those whose work effectively engages users and drives revenue. Additionally, Yidian develops a marketing database based on user interests, enhancing the precision of advertisement matching. Through its innovative approach, Yidian Zixun aims to provide a custom-tailored news experience that aligns with the unique preferences of each user.

Weijiechengpei

Series A in 2016
Weijiechengpei is a third-party logistics service provider based in urban areas, specializing in the distribution of goods for sectors such as catering, retail, and fresh e-commerce. Operating under the service brand Shanghai Kexin Logistics Co., Ltd., the company employs a model that combines consultation with logistics services. It focuses on B2B logistics management, particularly for restaurant and retail chains, and emphasizes logistics integration and the construction of B2B logistics networks. Weijiechengpei offers a range of services, including warehousing, distribution, packaging, and supply chain consulting, aimed at enhancing operational efficiency for its clients in the fast-moving consumer goods market and beyond.

meet you

Series E in 2016
Meet you is a female health management app that provides women's menstrual management consulting services. The app is providing mothers-to-be with rich pregnancy knowledge and intimate pregnancy reminders. Record the moment of baby growth and provide scientific advice on baby growth to mothers. At the same time, it provides girls with health, emotion, weight loss, beauty, and shopping knowledge posts, as well as a built-in real-girl communication area to accompany women during every important period.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.